For molecular diagnostics of lung cancer samples, often only a small amount of material is available. The ever-increasing number of biomarker testing is in contrast to the amount of material obtained. In that case, cytological specimens, such as serous effusion samples, are one possible option. Effusion samples were prepared as sediment smears or cytospins or as a cell block if needed. Suitable tumor cells areas were marked by a cytopathologist and used for molecular diagnostics, including fast track analysis, parallel sequencing, and/or fluorescence in situ hybridization. In 62 cases of malignant effusion with cells of pulmonary adenocarcinoma, molecular diagnostics were carried out. A fast-track result with the high-resolution melting met...
Malignant pleural effusion (MPE) is a useful specimen allowing for the evaluation of EGFR status in ...
Identification of driver mutations in lung adenocarcinoma has led to development of targeted agents ...
Identification of driver mutations in lung adenocarcinoma has led to development of targeted agents ...
Serous effusions constitute a significant part of the material processed and diagnosed by cytopathol...
Introduction:Pleural effusion is frequently observed in patients with advanced lung cancer. Although...
BACKGROUND: EGFR mutation is an emerging biomarker for treatment selection in non-small-cell lung ca...
Malignant pleural effusion (MPE) may be diagnosed by cytologic evaluation of pleural fluid, though f...
Background The study was conducted to evaluate the feasibility of using malignant pleural effusion (...
In advanced non-small-cell lung carcinomas epidermal growth factor receptor (EGFR) and KRAS testing ...
The current standard of care for advanced non-small-cell lung cancer is based on detecting actionabl...
BACKGROUND: The aim of this study was to validate clinical utilization of routinely prepared cytolog...
Epidermal growth factor receptor (EGFR) gene mutational analysis is critical for guiding the treatme...
Selection of lung cancer patients for therapy with tyrosine kinase inhibitors directed at EGFR requi...
Supernatant pleural effusions (PE) have shown to be a valuable source for the detection of driver mu...
Lung cancer is the malignancy with the highest mortality rate worldwide. Malignant pleural effusion ...
Malignant pleural effusion (MPE) is a useful specimen allowing for the evaluation of EGFR status in ...
Identification of driver mutations in lung adenocarcinoma has led to development of targeted agents ...
Identification of driver mutations in lung adenocarcinoma has led to development of targeted agents ...
Serous effusions constitute a significant part of the material processed and diagnosed by cytopathol...
Introduction:Pleural effusion is frequently observed in patients with advanced lung cancer. Although...
BACKGROUND: EGFR mutation is an emerging biomarker for treatment selection in non-small-cell lung ca...
Malignant pleural effusion (MPE) may be diagnosed by cytologic evaluation of pleural fluid, though f...
Background The study was conducted to evaluate the feasibility of using malignant pleural effusion (...
In advanced non-small-cell lung carcinomas epidermal growth factor receptor (EGFR) and KRAS testing ...
The current standard of care for advanced non-small-cell lung cancer is based on detecting actionabl...
BACKGROUND: The aim of this study was to validate clinical utilization of routinely prepared cytolog...
Epidermal growth factor receptor (EGFR) gene mutational analysis is critical for guiding the treatme...
Selection of lung cancer patients for therapy with tyrosine kinase inhibitors directed at EGFR requi...
Supernatant pleural effusions (PE) have shown to be a valuable source for the detection of driver mu...
Lung cancer is the malignancy with the highest mortality rate worldwide. Malignant pleural effusion ...
Malignant pleural effusion (MPE) is a useful specimen allowing for the evaluation of EGFR status in ...
Identification of driver mutations in lung adenocarcinoma has led to development of targeted agents ...
Identification of driver mutations in lung adenocarcinoma has led to development of targeted agents ...